IM
IMM.LSE ImmuPharma PLC
- Market cap
- GBX 22.0M
- P/E
- -
- P/B
- 11.37x
- ROE
- -774.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is IMM.LSE undervalued?
Graham numberThe Graham number of ImmuPharma PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ImmuPharma PLC fundamental analysis
No fundamental analysis for ImmuPharma PLC yet.
ImmuPharma PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ImmuPharma PLC
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas, including dermatology, gastroenterology, rheumatology, endocr…
Full company profileImmuPharma PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ImmuPharma PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 165K | 150K | 81.3K | 77.9K | 127K | 118K | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 43.4K | 150K | 81.3K | 77.9K | 127K | 118K | -118K | -37.6K | -63.9K | -35.3K | - |
| Operating Income | -6.59M | -7.23M | -8.08M | -6.28M | -5.59M | -6.59M | -3.03M | -3.06M | -2.68M | -2.54M | -3.20M |
| EBITDA | -6.19M | -6.86M | -7.82M | -6.65M | -6.84M | -8.70M | -2.91M | -3.03M | -2.61M | -2.51M | -3.20M |
| Net Income | -5.32M | -6.22M | -7.21M | -6.12M | -6.86M | -8.17M | -3.81M | -2.92M | -2.48M | -1.81M | -14.1M |
| EPS | -0.05 | -0.05 | -0.05 | -0.04 | -0.03 | -0.03 | -0.01 | -0.01 | -0.01 | 0.00 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 6.71M | 5.02M | 8.66M | 5.80M | 10.9M | 6.00M | 3.97M | 2.72M | 977K | 1.88M | 3.10M |
| Total Liabilities | 1.16M | 1.44M | 1.03M | 532K | 1.26M | 1.58M | 1.45M | 1.67M | 1.52M | 1.19M | 1.28M |
| Shareholders' Equity | 5.55M | 3.57M | 7.62M | 5.27M | 9.65M | 4.41M | 2.52M | 1.06M | -543K | 687K | 1.82M |
| Cash & Short-term Investments | 1.88M | 2.73M | 4.91M | 1.36M | 5.86M | 1.65M | 668K | 208K | 237K | 1.35M | 696K |
| Total Debt | 363K | 260K | 121K | 26.8K | 642K | 700.00 | 111.00 | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.49M | -4.42M | -4.72M | -4.22M | -3.33M | -4.83M | -2.35M | -1.36M | -1.77M | -2.37M | -1.43M |
| Capital Expenditure | 4.73K | 25.5K | 103K | 107K | 360K | 50.9K | 106K | 2.00 | 1.65K | 1.66K | 2.31K |
| Free Cash Flow | -6.49M | -4.45M | -4.82M | -4.33M | -3.69M | -4.88M | -2.45M | -1.36M | -1.77M | -2.37M | -1.44M |
| Ratios | |||||||||||
| ROE | -96.0% | -174.1% | -94.5% | -116.2% | -71.1% | -185.2% | -150.9% | -276.6% | - | -263.2% | -774.3% |
| ROA | -79.3% | -124.0% | -83.2% | -105.6% | -62.8% | -136.3% | -95.8% | -107.4% | -254.1% | -96.2% | -455.4% |
| Net Profit Margin | -3,230.9% | -4,135.9% | -8,866.8% | -7,858.8% | -5,415.8% | -6,906.6% | - | - | - | - | - |
| Debt to Equity | 0.07x | 0.07x | 0.02x | 0.01x | 0.07x | 0.00x | 0.00x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ImmuPharma PLC dividends
ImmuPharma PLC has not paid dividends in the last 9 fiscal years.
Last stock split: 1:1 on Aug 17, 2022.
Who owns ImmuPharma PLC
- Insiders 4.96%
- Institutions 16.29%
- Public & others 78.75%
- Shares outstanding 625M
- Free float 606M
ImmuPharma PLC company profile
- Company name
- ImmuPharma PLC
- Ticker
- IMM.LSE
- ISIN
- GB0033711010
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 7
- Fiscal year end
- December
- Address
- One Bartholomew Close, London, United Kingdom, EC1A 7BL
- Phone
- 44 20 7206 2650
- Website
- immupharma.co.uk
About ImmuPharma PLC
ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas, including dermatology, gastroenterology, rheumatology, endocrinology, and neurology; and CDx, a companion diagnostic, which is in clinical trial for the identification of immune endotype and treatment of various autoimmune diseases. The company is also involved in the development of Kapiglucagon, a proprietary glucagon prodrug, which is in pre-clinical trial for the treatment of type 1 diabetes; BioAMB, an amphotericin-B therapy, which is in pre-clinical trial for the treatment of invasive fungal infections, such as aspergillosis; and BioCIN, a vancomycin-based therapy, which is in pre-clinical trial for the treatment of gram-positive infections comprising methicillin-resistant staphylococcus aureus, sepsis, lower respiratory tract infections, osteomyelitis, and skin infections. It has collaboration arrangements with Avion Pharmaceuticals LLC and Centre National de la Recherche Scientifique for the development of P140 platform. The company was founded in 1999 and is headquartered in London, the United Kingdom.
ImmuPharma PLC management
8- Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A.Chairman & CEO · born 1956
- Dr. Timothy Gary Franklin M.B.A., Ph.D.COO & Director · born 1964
- Dr. Sebastien R. Goudreau Ph.D.Chief Scientific Officer & Director · born 1981
- Ms. Lisa BaderoonHead of Investor Relations & Non Executive Director · born 1966
- Ms. Ashley Louise Clarke A.C.A.Group CFO & Company Secretary
- Dr. Jean-Marie Geiger PharmD, MDHead of Clinical Development
- Dr. Laura Mauran-Ambrosino Ph.D.Head of Research & Development
- Ms. Lara E. Sucheston-CampbellHead of Clinical & Medical Affairs